Amicus Therapeutics, Inc. (FOLD)
Automate Your Wheel Strategy on FOLD
With Tiblio's Option Bot, you can configure your own wheel strategy including FOLD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FOLD
- Rev/Share 1.9409
- Book/Share 0.747
- PB 19.1367
- Debt/Equity 1.9218
- CurrentRatio 2.9863
- ROIC 0.1929
- MktCap 4411269934.0
- FreeCF/Share 0.0314
- PFCF 455.1924
- PE 221.8645
- Debt/Assets 0.5097
- DivYield 0
- ROE 0.0967
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | FOLD | Leerink Partners | Outperform | Market Perform | -- | $14.5 | Dec. 29, 2025 |
| Downgrade | FOLD | TD Cowen | Buy | Hold | -- | $14.5 | Dec. 22, 2025 |
| Initiation | FOLD | Citigroup | -- | Buy | -- | $17 | Dec. 17, 2025 |
| Upgrade | FOLD | Needham | Hold | Buy | -- | $14 | Sept. 18, 2025 |
| Upgrade | FOLD | Morgan Stanley | Equal Weight | Overweight | -- | $108 | July 17, 2025 |
| Downgrade | FOLD | Morgan Stanley | Overweight | Equal Weight | $17 | $12 | Dec. 13, 2024 |
| Initiation | FOLD | Jefferies | -- | Buy | -- | $18 | Sept. 6, 2024 |
News
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Neutral
Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.
Read More
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
Published: December 26, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics, Inc. (NasdaqGM: FOLD) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Amicus will receive $14.50 in cash for each share of Amicus that they own. KSF is seeking to determine whether this consideration and the process.
Read More
BioMarin: Amicus Buyout Sparks My Enthusiasm
Published: December 22, 2025 by: Seeking Alpha
Sentiment: Positive
BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example, sales of Brineura, approved for CLN2 disease, reached $48 million in Q3, up 29.7% year-on-year.
Read More
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
Published: December 19, 2025 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE , Dec. 19, 2025 /PRNewswire/ -- The Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read More
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
Published: December 19, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus shareholders. Halper Sadeh encourages Amicus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Amicu.
Read More
5 Biotech Stocks to Watch for Potential Upside
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
Read More
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus hits a 52-week high after an 87.6% six-month surge, driven by strong Galafold sales and rising uptake of Pombiliti + Opfolda.
Read More
Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 60.6% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
The Best Cheap Stocks Under $10 to Buy in December and 2026
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Today, we explore how investors can find the best-in-class cheap stocks trading for under $10 a share to buy now.
Read More
Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Can Galafold Continue to Drive Amicus' Top Line in 2026?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
FOLD leans on rising Galafold sales on the back of strong commercial execution as momentum builds into 2026.
Read More
Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Read More
Wall Street Analysts Think Amicus Therapeutics (FOLD) Could Surge 58.46%: Read This Before Placing a Bet
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 58.5% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 76.3% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
EVER, FOLD, LRCX and CBOE make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.
Read More
Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
FOLD's third-quarter earnings top estimates as rising Galafold and Pombiliti + Opfolda sales lift revenues by 19% year over year.
Read More
Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript
Published: November 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Amicus Therapeutics, Inc. ( FOLD ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - CEO, President & Director Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Nicolas Harford - Chief Financial Officer Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research Division Yuchen Ding - Jefferies LLC, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Maxwell Skor - Morgan Stanley, Research Division Joshua Fleishman - TD Cowen, Research Division Rick Miller - Cantor Fitzgerald & Co., …
Read More
Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.1 per share a year ago.
Read More
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Broker upgrades fuel optimism for Amicus Therapeutics, Micron and General Dynamics as earnings outlook strengthens.
Read More
3 Of My Favorite Biotech Stocks Under $10
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Positive
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.
Read More
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Read More
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda®
Read More
In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al. People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al.
Read More
The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Physicians file amicus brief opposing removal of religious exemptions to vaccines. Objections include components derived from pork or aborted fetal tissue.
Read More
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
Read More
About Amicus Therapeutics, Inc. (FOLD)
- IPO Date 2007-05-31
- Website https://amicusrx.com
- Industry Biotechnology
- CEO Bradley L. Campbell
- Employees 499